Genetic markers associated with early cancer-specific mortality following prostatectomy

Cancer

Volumn 119, Issue 13, 2013, Pages 2405-2412

  Liu, Wennuan ^a   Xie, Chunmei C ^a   Thomas, Christopher Y ^a   Kim, Seong Tae ^a   Lindberg, Johan ^b   Egevad, Lars ^c   Wang, Zhong ^a   Zhang, Zheng ^a   Sun, Jishan ^a   Sun, Jielin ^a   Koty, Patrick P ^a   Kader, A Karim ^d   Cramer, Scott D ^e   Bova, G Steven ^f   Zheng, S Lilly ^a   Grönberg, Henrik ^b   Isaacs, William B ^g   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

MYC; prostate cancer death; PTEN; somatic DNA copy number

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADAR GENE; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CHROMOSOME; COHORT ANALYSIS; COPY NUMBER ALTERATION; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; ONCOGENE MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PTEN GENE; RISK FACTOR; SERPINB5 GENE; TP53 GENE; TPD52 GENE; USP10 GENE;

ADULT; AGED; DNA COPY NUMBER VARIATIONS; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENES;

EID: 84879088895     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27954     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117:2883-2891.
3. Kibel AS, Ciezki JP, Klein EA, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol. 2012;187:1259-1265.
4. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708-1717.
5. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619-624.
6. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559-565.
7. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
8. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214-220.
9. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer:methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104:20007-20012.
10. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves:a nonparametric approach. Biometrics. 1988;44:837-845.
11. Ding Z, Wu CJ, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470:269-273.
12. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67:8504-8510.
13. Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer. 2002;34:363-371.
14. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007;97:678-685.
15. Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol. 2008;26:3930-3936.
16. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004;113:913-923.
17. Zafarana G, Ishkanian AS, Malloff CA, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer. 2012;118:4053-4062.
18. Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol. 2012;30:1857-1863.
19. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy:a proposal for a standardized definition. J Clin Oncol. 2006;24:3973-3978.
20. Bouchard C, Marquardt J, Brás A, Medema RH, Eilers M. Mycinduced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 2004;23:2830-2840.
21. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A. 2008;105:6584-6589.
22. Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet. 2009;5:e1000542.
23. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy:SWOG S9921 study. J Clin Oncol. 2011;29:2040-2045.
24. Montgomery B, Lavori P, Garzotto M, et al. Veterans Affairs Cooperative Studies Program study 553:Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008;72:474-480.
25. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685-689.